 LEXINGTON, Mass., Nov. 04, 2020 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including topline data from Keros Phase 1 clinical trial of KER-047, at the 62nd American Society of Hematology ASH Annual Meeting and Exposition, to be held as a virtual event from December 5-8, 2020. 